Abivax (ABVX) EUR0.01
Sell:€5.76Buy:€5.80
€0.05
(0.85%)
- This stock can be held in a
Stocks and Shares ISA€0.05
(0.85%)€0.05
(0.85%)Company Information
About this company
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Key people
Key facts
- EPIC-
- LocationFrance
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINFR0012333284
- Market cap€370.69m
- Employees62
- Shares in issue62.93m
- ExchangeEuronext Paris
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.